EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings
Abstract
Authors
S Crawford H Li B Srivastava P Martin J Gahn KA Rogers